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ent using echocardiographic parameters, CRT was harmful 
in those patients with narrow QRS complexes [8]. In more 
than 20 years of experience with CRT-related issues, we 
have deepened our knowledge about indication, implanta-
tion, evaluation, and optimisation of CRT. With the rapid 
development of the CRT technology new challenges arise.
This special issue of the Netherlands Heart Journal elu-
cidates current aspects of cardiac resynchronisation therapy. 
Wiegerinck et al. [9] describe the pathophysiological rela-
tionship between LBBB and dyssynchronous mechanical 
activation which creates LV dysfunction by ‘wasted work’. 
The worsening of LV function causes remodelling by neu-
rohumoral activation and asymmetric hypertrophy. The fact 
that these remodelling processes are caused by changes in 
the regulation of gene expression raises the question whether 
genetic predisposition can also play a role in CRT response. 
Possible answers to this question are discussed in the review 
article by Lahrouchi and Bezzina [10]. They found different 
expressions of genes encoding components of Ca2 + handling, 
β-adrenergic receptors, contractile proteins, and myocardial 
natriuretic peptide pre- and post-CRT. It remains unclear 
whether these changes in gene expression are truly induced 
by CRT itself or whether they are the result of improvement 
in LV function. Because of the complexity of the phenotype 
‘CRT responder’ and the intricate underlying genetic archi-
tecture, large studies will be necessary to identify genetic 
factors associated with volumetric CRT response.
Versteeg et al. [11] showed in a prospective study of 139 
CRT patients that patient-reported outcome assessed prior to 
CRT independently identifies poor survival and hospitalisa-
tion. It seems logical to assess patient-perceived symptoms 
of heart failure, functional limitations, and quality of life 
routinely before CRT implantation and during follow-up to 
improve their management. In the accompanying editorial 
comment ‘Patients predict their own outcome’, Kronborg 
In 1993, the cardiac surgeon Bakker et al. [1] introduced 
biventricular pacing as a novel method to treat heart failure 
by synchronous stimulation of the right and left ventricle. 
After this first-in-man implantation, the rapid develop-
ment of transvenous left ventricular (LV) leads and the 
implementation of biventricular pacing in implantable 
cardioverter/defibrillators have established cardiac resyn-
chronisation therapy (CRT) as a standard treatment of heart 
failure with systolic LV dysfunction and broad QRS com-
plexes. Although the milestone trials have proven the ben-
efit of CRT (reduction in mortality and morbidity, reverse 
remodelling, improvement of LV function), the prediction 
of CRT response still remains a challenge [2–6]. Because 
of the high number of CRT non-responders, especially in 
patients with unspecific widening of the QRS complex, 
class I indication for CRT was restricted to heart failure 
patients with typical left bundle branch block (LBBB) in 
the European Heart Rhythm Association guidelines update 
of 2013. Two-dimensional echocardiography is the most 
widely used noninvasive method for the evaluation of LV 
function and assessment of reverse remodelling after CRT; 
however it has as yet failed to play an additional role in 
determining the indication for CRT [7]. Furthermore, even 
though mechanical dyssynchrony was thought to be pres-
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and Nielsen [12] appeal for implementation of patient-
reported outcomes when taking care of these heart failure 
patients who need cardiac implantable devices. The ques-
tion remains whether interventions performed to improve 
patient-reported health status also influence the long-term 
outcome of CRT patients. Heart failure symptoms classified 
by NYHA and exercise capacity were the primary endpoints 
of the multicentre randomised trials at the beginning of the 
CRT era [2–6]. Later on, the evaluation of hospitalisation 
rate, survival, and reverse remodelling became more impor-
tant to convince the healthcare authorities about the value 
of CRT. Reverse remodelling can be assessed by echo-
cardiography with its limitations of imaging quality and 
interobserver variability. Van Everdingen et al. [13] criti-
cally discuss the role of echocardiography in their review 
article. The importance of measuring dyssynchrony to select 
patients for CRT seemed to increase with every new pub-
lished single-centre study until the multicentre PROSPECT 
trial brought disappointment to imaging cardiologists [7]. 
Ghani et al. [14] showed in their prospective observational 
single-centre study of 297 CRT patients that echocardio-
graphic assessment of mechanical dyssynchrony (apical 
rocking) predicted CRT super-responders with a good long-
term prognosis. Van ’t Sant et al. [15] showed that the 
amount of reverse remodelling can be a surrogate marker 
for long-term outcome only in patients with non-ischaemic 
cardiomyopathy. In ischaemic cardiomyopathy CRT may 
resolve LV dyssynchrony, however coronary artery disease 
still determines the patient’s prognosis.
One important, underestimated factor that influences CRT 
response is LV lead placement. Imaging techniques such as 
cardiac MRI tagging or deformation echocardiography can 
detect the segment of latest mechanical activation; however 
prior to CRT implantation the exact coronary venous anatomy 
is usually not known. So why don’t we measure the electrical 
delay in the side branches of the coronary sinus where the LV 
pacing lead will be implanted? Such an optimal lead position 
at the free wall of the LV may be more important in patients 
with ischaemic cardiomyopathy and non-typical LBBB. Van 
Stipdonk et al. [16] describe a new method to find instanta-
neously delayed LV lateral wall activation by electroanatom-
ical mapping in the coronary veins during CRT implantation. 
Especially for patients with non-LBBB QRS widening this 
new method facilitates optimal LV lead placement and may 
improve response to CRT [17]. In comparison with LV lead 
optimisation, little is known about the contribution of right 
ventricular (RV) pacing to CRT. Expert opinion about the 
necessity of RV pacing for CRT can be divided in the fol-
lowing two directions: (1) Biventricular pacing to optimise 
diastolic function and (2) LV pacing with fusion of intrinsic 
right bundle branch depolarisation to obtain optimal ventric-
ular synchronicity of depolarisation. In the contribution by 
Wu et al. [18] it was shown that in an invasive observational 
study of 41 CRT patients biventricular pacing improved 
haemodynamic response in comparison to only LV pacing 
in patients with impaired RV function. On the other hand, 
RV pacing ‘only’ can be harmful, especially for patients with 
impaired LV function. For these patients who develop heart 
failure during conventional pacemaker therapy an upgrade 
to CRT is indicated. However, the milestone trials about 
CRT included only ‘de novo’ CRT implants and the common 
opinion is that CRT upgrade procedures are more difficult 
and complicated compared with ‘de novo’ implants. In a ret-
rospective single-centre study Ter Horst et al. [19] showed 
that CRT upgrades were not more complex nor associated 
with more complications than ‘de novo’ CRT implantations. 
Notably, these results can only be applied to a tertiary centre 
with a high patient throughput and three highly experienced 
cardiologists who performed the procedures, as De Voogt 
pointed out [20]. The decision of an upgrade procedure to 
a more complex system has to be carefully considered. An 
‘upgrade’ to endocardial LV pacing might be much more 
complex than an upgrade from a conventional device to a 
CRT. The Eindhoven group has extensive experience with 
LV endocardial lead placement. They showed that the benefit 
of LV endocardial pacing is based on the absence of phrenic 
nerve stimulation and the free choice of LV lead placement 
independently of having a coronary vein at the target region. 
The most significant haemodynamic improvement of CRT 
with LV endocardial pacing was in the region of LV delayed 
electrical activation [21]. These data must motivate us to put 
all our efforts into placing the LV lead in the target region. 
Special catheter techniques for ‘getting the LV lead to the 
right spot’ are described by Jackson and Steen [22].
Several current aspects of cardiac resynchronisation 
therapy are highlighted in this special CRT issue. These 
reviews and original articles can give us new insights for 
daily clinical practice and provide inspiration for new 
research projects to further improve heart failure therapy 
with implantable cardiac devices for our patients.
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